ReoPro's launch program

Centocor Inc. said it sold $7.9 million of its ReoPro antiplatelet antibody to partner Eli Lilly and Co. in the first six weeks of sales. Lilly launched the GPIIb/IIIa inhibitor, which reduces acute cardiac ischemic complications in high risk patients undergoing angioplasty, on Feb. 13.

CNTO said the sales figure was on target with its internal estimates. Lilly did not disclose its sales figures, which analysts estimated at $50-80 million this year (see page B9).